| scholarly article | Q13442814 |
| P50 | author | Pamela DeRosse | Q57550196 |
| Katherine E Burdick | Q91221264 | ||
| Todd Lencz | Q37652358 | ||
| P2093 | author name string | Anil K Malhotra | |
| Alyson Kaplan | |||
| P2860 | cites work | Psychiatric comorbidities and schizophrenia | Q22242829 |
| Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people | Q24558606 | ||
| Rethinking psychosis: the disadvantages of a dichotomous classification now outweigh the advantages | Q24643013 | ||
| Neurocognitive and social functioning in schizophrenia. | Q51986093 | ||
| Cognitive functioning of long-term heavy cannabis users seeking treatment. | Q52014109 | ||
| Correlates of substance misuse in patients with first-episode schizophrenia and schizoaffective disorder. | Q52016145 | ||
| Cannabis dependence and psychotic symptoms in young people | Q52024293 | ||
| Neurocognitive and social functioning in schizophrenia: a 2.5 year follow-up study. | Q52167386 | ||
| Cannabis induces different cognitive changes in schizophrenic patients and in healthy controls. | Q52926271 | ||
| The temporal dynamics of relationships between cannabis, psychosis and depression among young adults with psychotic disorders: findings from a 10-month prospective study | Q57047605 | ||
| Cannabis use and outcome of recent onset psychosis | Q57403352 | ||
| Familial Predisposition for Psychiatric Disorder | Q57516808 | ||
| Drug abuse and/or dependence and better neuropsychological performance in patients with schizophrenia | Q58190172 | ||
| Disrupted in Schizophrenia 1 Genotype and Positive Symptoms in Schizophrenia | Q58865474 | ||
| Do cognitive impairments recover following cessation of cannabis use ? | Q60630751 | ||
| Lower negative symptom scores among cannabis-dependent patients with schizophrenia-spectrum disorders: preliminary evidence from an African American first-episode sample | Q80578981 | ||
| Defining a cognitive function decrement in schizophrenia | Q81551784 | ||
| Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review | Q28238516 | ||
| Causal association between cannabis and psychosis: examination of the evidence | Q28241735 | ||
| Cannabis and schizophrenia. A longitudinal study of Swedish conscripts | Q28283322 | ||
| Iowa gambling task in schizophrenia: a review and new data in patients with schizophrenia and co-occurring cannabis use disorders | Q31106608 | ||
| Does schizoaffective disorder really exist? A systematic review of the studies that compared schizoaffective disorder with schizophrenia or mood disorders | Q33295092 | ||
| Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study | Q33962711 | ||
| Neuropsychological performance in long-term cannabis users | Q34092892 | ||
| Substance abuse in schizophrenia: a review of the literature and a study of correlates in Sweden | Q34201663 | ||
| Rate of cannabis use disorders in clinical samples of patients with schizophrenia: a meta-analysis | Q34235419 | ||
| Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: follow-up study of 535 incident cases | Q34471622 | ||
| Cannabis, vulnerability, and the onset of schizophrenia: an epidemiological perspective | Q34509505 | ||
| Cannabis use and age at onset of schizophrenia | Q34545981 | ||
| Cannabis use predicts future psychotic symptoms, and vice versa | Q34557027 | ||
| Effects of chronic marijuana use on human cognition | Q34723633 | ||
| Psychological and social sequelae of cannabis and other illicit drug use by young people: a systematic review of longitudinal, general population studies | Q35774562 | ||
| Does gender contribute to heterogeneity in criteria for cannabis abuse and dependence? Results from the national epidemiological survey on alcohol and related conditions | Q35866473 | ||
| The genetics of symptom-based phenotypes: toward a molecular classification of schizophrenia | Q37076517 | ||
| Abbreviated neuropsychological assessment in schizophrenia: prediction of different aspects of outcome | Q37157753 | ||
| What we know: findings that every theory of schizophrenia should explain. | Q37159625 | ||
| Defining the schizophrenia spectrum: issues for genetic linkage studies | Q37499933 | ||
| Comorbid substance use and age at onset of schizophrenia | Q39747250 | ||
| Understanding differences in marijuana use among urban Black and suburban White high school students from two U.S. community samples | Q39752926 | ||
| Clinical characteristics of adolescents later hospitalized for schizophrenia | Q40618645 | ||
| Influence of cannabis abuse on schizophrenic psychopathology | Q41113315 | ||
| Relevance of drug use in clinical manifestations of schizophrenia | Q44005137 | ||
| IQ and mental disorder in young men. | Q44525510 | ||
| Cannabis use prior to first onset psychosis predicts spared neurocognition at 10-year follow-up | Q44537020 | ||
| Cannabis use and psychosis: a longitudinal population-based study. | Q44820509 | ||
| First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol | Q44827853 | ||
| Substance abuse and the onset of schizophrenia. | Q50990164 | ||
| Cannabis and schizophrenia: results of a follow-up study. | Q51090957 | ||
| Dysbindin genotype and negative symptoms in schizophrenia. | Q51920695 | ||
| Correlates of substance abuse in adolescents with treatment-refractory schizophrenia and schizoaffective disorder. | Q51934012 | ||
| Early adolescent cannabis exposure and positive and negative dimensions of psychosis. | Q51937432 | ||
| Specific cognitive deficits and differential domains of social functioning impairment in schizophrenia. | Q51960885 | ||
| P433 | issue | 1-3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | schizophrenia | Q41112 |
| P304 | page(s) | 95-100 | |
| P577 | publication date | 2010-05-18 | |
| P1433 | published in | Schizophrenia Research | Q7431607 |
| P1476 | title | Cannabis use disorders in schizophrenia: effects on cognition and symptoms | |
| P478 | volume | 120 |
| Q53762498 | Age at onset of non-affective psychosis in relation to cannabis use, other drug use and gender. |
| Q36354947 | An fMRI Study of Neuronal Activation in Schizophrenia Patients with and without Previous Cannabis Use. |
| Q52600030 | Associations between adolescent cannabis use and brain structure in psychosis. |
| Q52151974 | Attentional dysfunction in abstinent long-term cannabis users with and without schizophrenia. |
| Q34530176 | BRIEF REPORT: THE IMPACT OF ALCOHOL AND CANNABIS MISUSE ON COGNITION AMONG INDIVIDUALS WITH SCHIZOPHRENIA. |
| Q60303884 | Cannabis acute use impacts symptoms and functionality in a cohort of antipsychotic naïve First Episode of Psychosis individuals |
| Q50993509 | Cannabis and cognitive performance in psychosis: a cross-sectional study in patients with non-affective psychotic illness and their unaffected siblings. |
| Q38950359 | Cannabis and development of dual diagnoses: A literature review |
| Q27024404 | Cannabis and psychosis: Neurobiology |
| Q34634045 | Cannabis use and cognitive dysfunction |
| Q50434552 | Cannabis use and cognitive function in first episode psychosis: differential effect of heavy use. |
| Q38884449 | Cognition and psychopathology in first-episode psychosis: are they related to inflammation? |
| Q35534902 | Cognitive and clinical outcomes associated with cannabis use in patients with bipolar I disorder. |
| Q38124448 | Comorbid substance use disorder in schizophrenia: a selective overview of neurobiological and cognitive underpinnings |
| Q35229933 | Comorbid substance use disorders in schizophrenia: a latent class approach |
| Q51660111 | Correlated covariates in ANCOVA cannot adjust for pre-existing differences between groups |
| Q90263481 | Differential effects of Δ9-tetrahydrocannabinol dosing on correlates of schizophrenia in the sub-chronic PCP rat model |
| Q30366949 | Does Cannabis Cause, Exacerbate or Ameliorate Psychiatric Disorders? An Oversimplified Debate Discussed |
| Q39517216 | Executive functioning in individuals with schizophrenia and/or cocaine dependence. |
| Q89719142 | Factors Moderating the Association Between Cannabis Use and Psychosis Risk: A Systematic Review |
| Q61808111 | Medical cannabis patterns of use and substitution for opioids & other pharmaceutical drugs, alcohol, tobacco, and illicit substances; results from a cross-sectional survey of authorized patients |
| Q33762494 | Neurocognitive functioning of individuals with schizophrenia: using and not using drugs |
| Q39480548 | Premorbid cannabis use is associated with more symptoms and poorer functioning in schizophrenia spectrum disorder |
| Q37705759 | Stress-induced dopamine response in subjects at clinical high risk for schizophrenia with and without concurrent cannabis use |
| Q34531537 | The Cannabis Pathway to Non-Affective Psychosis may Reflect Less Neurobiological Vulnerability |
| Q50980365 | The differential effect of illicit drug use on cognitive function in first-episode psychosis and healthy controls. |
| Q37061404 | The neural correlates of mental rotation abilities in cannabis-abusing patients with schizophrenia: an FMRI study |
| Q38639956 | Understanding marijuana's effects on functional connectivity of the default mode network in patients with schizophrenia and co-occurring cannabis use disorder: A pilot investigation. |
Search more.